Eli Lilly (LLY) is cutting prices for starting doses of Zepbound single-dose vials on its LillyDirect direct-to-consumer platform.
With a valid prescription, patients can get a 2.5 mg vial for $299 per month, down from $349 previously, and a 5 mg vial for $399, lower than $499 previously. All other higher doses, from 7.5 mg to 15 mg, remain priced at $449/month through the Self Pay program.
The announcement follows Novo Nordisk (NVO) cutting prices of weight loss drug rival Wegovy in the second half of November to match Zepbound for a limited time, with 0.25 mg and 0.5 mg Wegovy and Ozempic priced $199 per month to new self-pay patients up to March 31, 2026.
After the first two months, Wegovy and Ozempic will be offered through Novo’s direct-to-consumer NovoCare portal for $349 per month—about 30% below current self-pay pricing. The self-pay cost of Ozempic 2mg will remain $499 per month.
With Eli Lilly’s (LLY) latest discounts, its low-dose variants come in lower than Novo’s obesity drugs for the same dosage.